Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ESGIC-PLUS

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

Standard Dose
500MG;50MG;40MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview ESGIC-PLUS is listed in Drugs@FDA under application 089451 (ANDA).

Marketing status: Discontinued Active ingredient ACETAMINOPHEN; BUTALBITAL; CAFFEINE Form and strength TABLET;ORAL - 500MG;50MG;40MG Sponsor MIKART Submission history Latest submission status date: 2002-08-13 00:00:00.

Structured Monograph

Clinical summary

Approval overview ESGIC-PLUS is listed in Drugs@FDA under application 089451 (ANDA). Marketing status: Discontinued Active ingredient ACETAMINOPHEN; BUTALBITAL; CAFFEINE Form and strength TABLET;ORAL - 500MG;50MG;40MG Sponsor MIKART Submission history Latest submission status date: 2002-08-13 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.
ESGIC-PLUS (ACETAMINOPHEN; BUTALBITAL; CAFFEINE) | Drug Monograph | MedicHelpline